Tecentriq CAS 1380723-44-3

Keytruda CAS 1374853-91-4
05/12/2018
Vitamin D2 CAS 50-14-6
05/12/2018
Show all

Model: MOS 1380723-44-3
Place of Origin: Zhejiang,China (Mainland)
Name: Tecentriq
CAS: 1380723-44-3

Tecentriq

CAS: 1380723-44-3

Pharmacological action and mechanism

Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells

and may contribute to the inhibition of anti-tumor immune responses in tumor

microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1

receptors and antigen presentation showed that the cells inhibited the activity of

cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a

monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1

and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune

responses, including activation of anti-tumor immune responses, does not induce

antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition

of pd-l1 activity leads to reduced tumor growth.

We can customize according to customer’s requirement

if you have any question pls mail us or call us

Reviews

There are no reviews yet.

Be the first to review “Tecentriq CAS 1380723-44-3”